ISO 14155-2020医疗器械临床实验管理规范
VIP免费
Clinical investigation of medical
devices for human subjects — Good
clinical practice
Investigation clinique des dispositifs médicaux pour sujets humains —
Bonne pratique clinique
© ISO 2020
INTERNATIONAL
STANDARD
ISO
14155
Third edition
2020-07
Reference number
ISO 14155:2020(E)
Copyright International Organization for Standardization
Provided by IHS Markit under license with Standards Council of Canada
Not for Resale, 08/01/2020 07:24:26 MDT
No reproduction or networking permitted without license from IHS
--`,``,,`,``,`,,`,,,,,,,,,````-`-`,,`,,`,`,,`---
ISO 14155:2020(E)
ii © ISO 2020 – All rights reserved
COPYRIGHT PROTECTED DOCUMENT
© ISO 2020
Website: www.iso.org
Copyright International Organization for Standardization
Provided by IHS Markit under license with Standards Council of Canada
Not for Resale, 08/01/2020 07:24:26 MDT
No reproduction or networking permitted without license from IHS
--`,``,,`,``,`,,`,,,,,,,,,````-`-`,,`,,`,`,,`---
ISO 14155:2020(E)
Foreword ..........................................................................................................................................................................................................................................v
1 Scope ................................................................................................................................................................................................................................. 1
2 Normative references ...................................................................................................................................................................................... 1
..................................................................................................................................................................................... 1
4 Summary of good clinical practice (GCP) principles ....................................................................................................... 9
5 Ethical considerations .................................................................................................................................................................................10
........................................................................................................................................................................................................ 10
....................................................................................................................................10
.................................................................................................................... 10
.............................................................................................................. 11
5.5 Responsibilities ...................................................................................................................................................................................11
...................................................................................................11
................................................................................................................................................................................... 11
................................................................................................................................................. 11
................................................................................................... 12
................................................................................................... 12
..................................................................... 12
................................................................................................................................................................. 12
...............................................................................................................................................................................13
................................................................................................................................................................................... 13
..................................................................................................... 13
........................................................................................14
..............................................................................................15
................................................................................................................................ 17
...........................................................................................................................................................17
6 Clinical investigation planning ...........................................................................................................................................................17
........................................................................................................................................................................................................ 17
..............................................................................................................................................................................
...................................................................................................................................................................................
.....
............................................................................................................................
....................................................................................
............................................................................................................................................
.....................................................................................................................................................
............................................................................................................................................................ 20
................................................................................................................................................................................... 20
........................................................................................................................................................ 21
......................................................................................................................................................................................... 21
.................................................................................................................................................................................................... 21
...................................................................................................................................21
7 Clinical investigation conduct ..............................................................................................................................................................22
........................................................................................................................................................................................................ 22
....................................................................................................................................................... 22
..................................................................................................................................................22
.........................................................................................................................22
............................................................................................................. 22
7.4.2 Adverse events ................................................................................................................................................................ 23
......................................................................................................................................................23
..................................................23
...................................................................................... 24
7.5.1 Amendments .................................................................................................................................................................... 24
....................................................................................................................................... 24
© ISO 2020 – All rights reserved iii
Contents
Copyright International Organization for Standardization
Provided by IHS Markit under license with Standards Council of Canada
Not for Resale, 08/01/2020 07:24:26 MDT
No reproduction or networking permitted without license from IHS
--`,``,,`,``,`,,`,,,,,,,,,````-`-`,,`,,`,`,,`---
摘要:
展开>>
收起<<
Clinicalinvestigationofmedicaldevicesforhumansubjects—GoodclinicalpracticeInvestigationcliniquedesdispositifsmédicauxpoursujetshumains—Bonnepratiqueclinique©ISO2020INTERNATIONALSTANDARDISO14155Thirdedition2020-07ReferencenumberISO14155:2020(E)CopyrightInternationalOrganizationforStandardizationProvi...
声明:如果您的权利被侵害,请联系我们的进行举报。
相关推荐
-
RBA8.0官方中文版VIP免费
2025-11-16 16 -
新版RBA责任商业联盟一整套文件(含管理手册、全套程序文件及对应表单)
2025-11-17 28 -
最新最全面RBA(原EICC)社会责任程序文件(77个程序+相关表格)
2025-11-17 24 -
RBA-SP-067 供应商分包商实施RBA管理程序
2025-11-18 17 -
RBA-SP-066 记录管理程序
2025-11-18 19 -
RBA-SP-065 文件管理程序
2025-11-18 14 -
RBA-SP-064 纠正和预防措施管理程序RBA8.0
2025-11-18 22 -
RBA-SP-063 管理评审控制程序
2025-11-18 15 -
RBA-SP-062 内部审核管理程序
2025-11-18 22 -
RBA-SP-006 劳务派遣管理程序
2025-11-18 25
作者:多多猪
分类:法规规范
价格:50质量币
属性:90 页
大小:1.33MB
格式:PDF
时间:2025-09-17

